血液透析对转化生长因子β1及补体调节蛋白CD59基因表达的影响

目的　研究不同透析膜对维持性血液透析 (MHD)患者外周血转化生长因子 β1及补体调节蛋白CD5 9活性表达的影响。方法　通过流式细胞术和酶联免疫吸附法测定长期采用铜仿膜 (CU)与聚砜膜 (PSU)透析患者外周血TGF β1水平及CD5 9活性表达。结果　MHD患者血浆TGF β1水平明显增加 (P <0 .0 5 ) ,其中CU组为 (81.7± 8.7)ng mL ;PSU组为 (6 4 .3±8.3)ng mL ,与正常对照组 (49.3± 6 .1)ng mL相比均有显著差异 (P <0 .0 1,P <0 .0 5 ) ;而PSU组与CU组相比 ,外周血TGF β1水平明显下降 (P <0 .0 5 )。CD5 9在正常人外周血单个核细胞中无表达 ,而在尿毒症未透析组及血透组均有表达 ,其中未透析组表达较低 ,而血透组表达较高 ,CU膜血透组较PSU血透组表达要高 (P <0 .0 5 )。经相关分析结果显示 :CU组与PSU组内TGF β1水平与CD5 9表达均呈现良好的相关性 (r=0 .6 4 0 9与 0 .5 83,P <0 .0 5 )。 结论　血液透析通过血液 透析膜间相互反应可活化补体 ,诱导外周血单个核细胞 (PBMC)合成TGF β1增多 ,而增高的TGF β1水平可上调CD5 9基因表达 ,抑制补体异常活化造成的细胞破坏 ,对机体具有代偿性保护意义。然而不同透析膜如CU和PSU对MHD患者TGF β1与CD5 9的影响有所不同 ,这些变化与透析膜的生物相容性有关     

优化的贴片型测量探头及其生物医学应用研究

采用时域有限差分（FDTD）法结合遗传算法（GA）优化设计了适用于浅表生物组织高频测量的宽带同轴贴片探头，并用该探头测量了人体背部1～7GHz频带内的反射特性。优化设计出的圆形同轴贴片探头具有轴对称特点，辐射近场在生物组织中透人深、反射系数的频率响应特性好。所获得的人体背部反射特性的测量结果将为背部浅表组织电特性的重建提供有利的依据。     

切应力作用下肾近端小管上皮细胞纤溶酶原激活物(tPA和uPA)表达的变化及意义

检测切应力作用下肾近端小管上皮细胞纤溶酶原激活物tPA和uPA mRNA表达的变化,探讨糖尿病肾病早期小管间质细胞外基质重塑的可能机制.用5 dyn/cm2和10 dyn/cm2的切应力处理肾近端小管上皮细胞(NRK-52E),作用时间分别为1、3和6 h,用RT-PCR法检测tPA及uPA mRNA的表达.结果表明:切应力呈大小和时间依赖性下调肾小管上皮细胞tPA及uPA mRNA的表达.在糖尿病肾病早期,高滤过引起的切应力增加可抑制肾近端小管上皮细胞tPA和uPA mRNA表达,导致肾小管间质纤维蛋白溶解活性降低,参与小管间质细胞外基质的重塑.     

阿托伐他汀对Lewis大鼠实验性自身免疫性心肌炎作用的研究

目的： 探讨阿托伐他汀对实验性自身免疫性心肌炎(EAM）大鼠Th1/Th2偏离的影响及对EAM的治疗价值。方法: 6-8周雄性Lewis大鼠31只，其中8只作为正常对照；23只以猪心肌肌球蛋白免疫制成EAM模型，免疫后随机分为阿托伐他汀大剂量（10 mg·kg^-1·d^-1）组、小剂量（1 mg·kg^-1·d^-1）组和未治疗组，连续用药 21 d。第 21 d，行超声心动图检测；取心肌组织，观察大体及镜下炎症程度；ELISA检测血浆IL-2、IL-4、IL-10及IFN-γ等细胞因子水平,并以IFN-γ/IL-4比值作为Th1/Th2偏离方向指标。结果: 阿托伐他汀使EAM大鼠心室肥厚减轻，LVEDd降低，射血分数增加；心脏重量/体重比值及炎症程度分级显著降低；Th1型细胞因子(IFN-γ, IL-2)水平降低，Th2型细胞因子水平(IL-4, IL-10)升高。3组间TC、TG及HDL-C水平未见明显差异。结论: 阿托伐他汀使Th1/Th2平衡向Th1方向偏离，抑制EAM炎症反应。表明阿托伐他汀的免疫调节效应及在自身免疫病治疗中的应用前景。     

Ovarian stimulation by clomiphene citrate and hMG in combination with cetrorelix acetate for ICSI cycles

BACKGROUND: The introduction of GnRH antagonists such as cetrorelix acetate has made possible the simplification of ovarian stimulation. However, the most effective protocol for their administration has not yet been clearly defined. METHODS: Forty women with male-factor infertility undergoing 40 ICSI cycles were included in the study. Clomiphene citrate at 100 mg a day was given from cycle day 3 through day 7. hMG at 150 IU was given on cycle days 4, 6 and 8, and was adjusted from day 9 according to the follicular and hormone responses. Cetrorelix acetate at 2.5 mg was administered when the leading follicle reached 14 mm. The remaining 0.5 mg was divided into two 0.25 mg injections for possible later use. Serum FSH, LH, estradiol and progesterone levels were measured daily from the day of cetrorelix acetate injection until hCG was given. RESULTS: Serum LH level was suppressed effectively for 4 days. Four patients (10%) needed one or two additional injections of 0.25 mg cetrorelix acetate. No premature LH surge was detected in any of the women treated. Sixteen women became pregnant (40%), of which 14 pregnancies (35%) were ongoing at the time of writing. CONCLUSIONS: This study demonstrates that this new protocol is feasible for couples with male-factor infertility undergoing ICSI.     

The RANTES promoter polymorphism: a genetic risk factor for near-fatal asthma in Chinese children

BACKGROUND: RANTES promoter polymorphisms were found associated with asthma/atopy in some studies but not others, possibly reflecting the genetic heterogeneity among different ethnicities and different asthma severity. OBJECTIVE: The purpose of this investigation was to test the genetic association between the RANTES -28C/G and -403G/A polymorphisms and asthma/atopy in a cohort of Chinese children, with particular emphasis on those patients who had experienced life-threatening asthma attacks. METHODS: Forty-eight children with near-fatal asthma, 134 children with mild-to-moderate asthma, 69 children with allergic disorders but no asthma, and 107 nonasthmatic nonatopic control children were genotyped through use of a PCR-based assay. RESULTS: No significant difference was demonstrated for frequency of the RANTES -28C/G polymorphism when the mild-to-moderate asthma, atopic/nonasthmatic, and normal control groups were compared. The RANTES -28G allele was present in a significantly higher proportion of the children with near-fatal asthma compared with the nonasthmatic nonatopic controls (odds ratio, 2.93 [1.41-6.06]; P =.006) and the children with mild-to-moderate asthma (odds ratio, 3.52 [1.73-7.16]; P =.001). The frequency of -28G allele carriage correlated with asthma severity. The RANTES -28G allele was also associated with an increased blood eosinophil count and a higher degree of bronchial hyperresponsiveness. The RANTES -403G/A polymorphism did not influence asthma/atopy susceptibility, blood eosinophil count, or bronchial hyperresponsiveness. Interestingly, a higher frequency of -403A allele carriage was observed in the moderate asthma subgroup compared with the mild asthma analog. CONCLUSIONS: We conclude that the RANTES -28C/G polymorphism exacerbates asthma severity, representing a genetic risk factor for life-threatening asthma attacks in Chinese children. In addition, the linkage disequilibrium between these 2 polymorphisms is a potential confounder that must be considered in the design and interpretation of RANTES gene association studies.     

Cartilage regeneration using slow release of bone morphogenetic protein-2 from a gelatin sponge to treat experimental canine tracheomalacia: a preliminary report

We investigated whether saber sheath-type tracheomalacia could be treated by the slow release of bone morphogenetic protein (BMP)-2 from a gelatin sponge. A 1 cm gap was made in the middle portion of each of 10 consecutive tracheal cartilage rings in the canine cervix (control group, n = 3), then a gelatin sponge containing 12 microg of BMP-2 solution was implanted in the gap (12 microg group, n = 3). In another group (120 microg + P group, n = 3), the implanted gelatin sponge contained 120 microg of BMP-2 solution, and the gap was covered with periosteum. All of the control dogs developed saber sheath-type tracheomalacia, whereas tracheomalacia was not observed in the 12 microg and 120 microg + P groups. In the 12 microg group, fibrous cartilage was observed at the ends of the cartilage stumps. In the 120 microg + P group, newly formed bone and cartilage were observed to form a bridge between the cartilage stumps. The regeneration of cartilage or bone induced by the slow release of BMP-2 from a gelatin sponge might be useful for treatment of tracheomalacia.